Peter Neu1. 1. Jüdisches Krankenhaus Berlin - Akademisches Lehrkrankenhaus, Charité - Universitätsmedizin Berlin, Heinz-Galinksi-Str. 1, 13347, Berlin, Deutschland. peter.neu@jkb-online.de.
Abstract
BACKGROUND: Gamma-hydroxybutyrate (GHB) and its precursors have gained popularity over the last decade as a drug in the party and club scene; however, the clinical knowledge of these substances is low. In the literature there have been case reports of severe dependence and withdrawal but there is a lack of systematic knowledge about the clinical course and complications of detoxification treatment. OBJECTIVE: The aim of this article is to evaluate the prevalence, treatment course, complications and compliance of GHB patients seeking inpatient qualified detoxification treatment (QDT). METHODS: A retrospective evaluation of the hospital charts of all patients admitted to this clinic in 2017 for QDT of GHB. The Jewish Hospital in Berlin (Jüdisches Krankenhaus Berlin) provides specialized inpatient units for addictive diseases and a general intensive care unit. The control population came from a prospective study of all patients with addictive diseases who were treated in the same hospital in 2012. RESULTS: In 2017 a total of 18 patients with GHB addiction were treated in this hospital. This corresponds to a 1‑year prevalence of 2.28% of all addictive diseases in this year. During detoxification treatment 52% of the GHB patients had to be temporarily transferred to the intensive care unit, 5% had to be temporarily mechanically ventilated and 26% suffered from withdrawal delirium. Of the patients 42% terminated treatment prematurely against medical advice. CONCLUSION: Withdrawal treatment from GHB is a severe and potentially dangerous condition, the prevalence of complications was higher than for most other drugs and the rate of intensive care and withdrawal delirium was very high. Further studies are urgently needed with the aim of reducing the complication rates of GHB withdrawal and enhancing therapy adherence.
BACKGROUND:Gamma-hydroxybutyrate (GHB) and its precursors have gained popularity over the last decade as a drug in the party and club scene; however, the clinical knowledge of these substances is low. In the literature there have been case reports of severe dependence and withdrawal but there is a lack of systematic knowledge about the clinical course and complications of detoxification treatment. OBJECTIVE: The aim of this article is to evaluate the prevalence, treatment course, complications and compliance of GHBpatients seeking inpatient qualified detoxification treatment (QDT). METHODS: A retrospective evaluation of the hospital charts of all patients admitted to this clinic in 2017 for QDT of GHB. The Jewish Hospital in Berlin (Jüdisches Krankenhaus Berlin) provides specialized inpatient units for addictive diseases and a general intensive care unit. The control population came from a prospective study of all patients with addictive diseases who were treated in the same hospital in 2012. RESULTS: In 2017 a total of 18 patients with GHB addiction were treated in this hospital. This corresponds to a 1‑year prevalence of 2.28% of all addictive diseases in this year. During detoxification treatment 52% of the GHBpatients had to be temporarily transferred to the intensive care unit, 5% had to be temporarily mechanically ventilated and 26% suffered from withdrawal delirium. Of the patients 42% terminated treatment prematurely against medical advice. CONCLUSION: Withdrawal treatment from GHB is a severe and potentially dangerous condition, the prevalence of complications was higher than for most other drugs and the rate of intensive care and withdrawal delirium was very high. Further studies are urgently needed with the aim of reducing the complication rates of GHB withdrawal and enhancing therapy adherence.
Entities:
Keywords:
Complications; Delirium; Detoxification; Gamma-Hydroxybutyrate (GHB); Intensive care unit
Authors: Rudolf Brenneisen; Mahmoud A Elsohly; Timothy P Murphy; Joseph Passarelli; Stefan Russmann; Salvatore J Salamone; David E Watson Journal: J Anal Toxicol Date: 2004 Nov-Dec Impact factor: 3.367
Authors: Martijn S van Noorden; Lieselotte C A M van Dongen; Frans G Zitman; Ton A C M Vergouwen Journal: Gen Hosp Psychiatry Date: 2008-12-25 Impact factor: 3.238
Authors: Mauro A M Carai; Giancarlo Colombo; Roberta Reali; Salvatore Serra; Ignazia Mocci; M Paola Castelli; Giorgio Cignarella; Gian Luigi Gessa Journal: Eur J Pharmacol Date: 2002-04-26 Impact factor: 4.432
Authors: Harmen Beurmanjer; J J Luykx; B De Wilde; K van Rompaey; V J A Buwalda; C A J De Jong; B A G Dijkstra; A F A Schellekens Journal: CNS Drugs Date: 2020-06 Impact factor: 5.749